SPOTLIGHT: FDA committee ponders Genasense
Genta is awaiting the outcome of an FDA advisory meeting today, which will help determine the fate of its leukemia therapy Genasense. Yesterday, Genta's stock took a dive after FDA staffers questioned its effectiveness in newly released comments. The response rate to the therapy was 17 percent, compared to 7 percent for chemotherapy alone. The goal was 20 percent. "The study approached, but did not quite achieve statistical significance for its primary endpoint," the company noted. Report
Comments